| Ranbaxy Laboratories Ltd has informed BSE that the Board has decided to hold an Extra Ordinary General Meeting of the Company would be held on July 15, 2008 to seek requisite approvals from shareholders.
Ranbaxy Laboratories Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on July 15, 2008, inter alia, to transact the following business:
1. Authority to the Board of Directors to create, offer, issue and allot Equity Shares and Warrants to Daiichi Sankyo Company, Ltd, incorporated and existing under the Laws of Japan and having its Registered Office at 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo-103-8426 (Japan) as per following details:
a) 46,258,063 fully paid Equity Shares, of Rs 5 each at a premium of Rs 732 per share, being the price higher than the price determined as per Chapter XIII of the SEBI (Disclosure and Investor Protection) Guidelines, 2000 (the SEBI Guidelines).
b) 23,834,333 Warrants - each Warrant exercisable between six months to eighteen months from the date of allotment at the option of the warrant holder for one fully paid Equity Share of the Company of Rs 5 each at a price of Rs 737, being the price higher than the price determined as per the SEBI Guidelines,
subject to necessary provision and approvals.
The 'Relevant Date' as per the SEBI Guidelines for determination of applicable price for issue of the aforesaid Equity Shares and Warrants is June 15, 2008.
2. To revise the ceiling of remuneration of Mr. Malvinder Mohan Singh, Chief Executive Officer and Managing Director of the Company effective January 01, 2008 such that his Salary, Allowances and Perquisites shall not exceed Rs 25 Crores per annum and authority to the Board to fix actual remuneration of Mr. Malvinder Mohan Singh, Chief Executive Officer and Managing Director and revise it from time to time.
3. Amendment to the existing Employees Stock Option Scheme(s) of the Company to the effect that maximum number of stock options that may be granted to individual management employee in a year be increased from 40,000 to 3,00,000.
(As per BSE Announcement website dated on 20/06/2008)
Ranbaxy Laboratories Ltd has informed BSE that the members of the Company at the Extra-ordinary General Meeting (EGM) held on July 15, 2008, have unanimously approved all the Resolutions proposed in the Notice dated June 16, 2008; brief details of the same are given below:
1. Issue of following Securities on a preferential basis to Daiichi Sankyo Company Ltd, Japan, as per details given below:
a) 46,258,063 fully paid Equity Shares of Rs 5 each at a premium of Rs 732 per share;
b) 23,834,333 Warrants - each Warrant exercisable between six months to eighteen months from the date of allotment at the option of the warrant holder for one fully paid Equity Share of the Company of Rs 5 each at a price of Rs 737.
2. Revision in ceiling of remuneration of Mr. Malvinder Mohan Singh, Chief Executive Officer and Managing Director of the Company effective January 01, 2008 such that his Salary, Allowances and Perquisites shall not exceed Rs 25 Crores per annum.
3. Amendment in the existing Employees Stock Option Scheme(s) of the Company to the effect that maximum number of stock options that may be granted to individual management employees in a year be increased from 40,000 to 3,00,000.
(As per BSE Announcement Website dated on 15/07/2008) |
| The Board of Directors of the has approved the following subject to the requisite approvals :
1. Listing of the Securities of the Company at a Stock Exchange in USA either through conversion of existing Global Depositary Receipts (GDRs) into American Depositary Receipts (ADRs) and / or through issuance of fresh security / instrument.
2. Raising of resources through appropriate securities such as FCCBs and / or GDRs
and / or ADRs and / or any other appropriate security / instrument upto USD 1.5 Billion equivalent from time to time.
3. Borrowing in excess of paid-up share capital and free reserves of the Company upto Rs 50000 million.
4. Increase in Authorised Share Capital of the Company from Rs 2000 million to Rs 3000 million.
5. Increase in the limit of shareholding by FIIs upto 50% of the share capital of the Company with effect from such date(s) and in such tranches / stages as may be decided by the Board from time to time.
6. Convening of an Extra-Ordinary General Meeting of the Company to be held on October 21, 2005 for seeking necessary approvals of the Shareholders.
7. Notice to the Shareholders for seeking consent through postal ballot for divestment of Allied Businesses Port-folio consisting of :
a. Ranbaxy Fine Chemicals Ltd. (a wholly owned subsidiary).
b. Animal Healthcare Business.
c. Diagnostic Business and appointment of Mr. Sooraj Kapur, Practising Company
Secretary (Retired Registrar of Companies, NCT of Delhi & Haryana) as Scrutinizer for conducting the postal ballot.
Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of Notice of EGM of the company to
be held on October 21, 2005.
(As per NSE Bulletin dated on 04/10/2005)
The company has informed that the members at the Extra Ordinary General Meeting (EGM) held on October 21, 2005, inter alia, have approved the following:
1. Raising of financial resources through appropriate securities such as FCCBs and / or GDRs and / or ADRs and /or any other appropriate security / instrument upto USD 1.5 Billion equivalent in one or more tranches from time to time.
2. Increase in Authorised Share Capital of the Company from Rs 2000 million to Rs 3000 million and consequential amendments in the Memorandum and Articles of Association.
3. Borrowing in excess of Paid-up share capital and free reserves of the Company upto Rs 50,000 million.
4. Increase in the limit of shareholding of FIIs upto 50% of the Share Capital of the Company with effect from such date(s) and in such tranches / stages as may be decided by the Board from time to time.
(As per BSE Bulletin dated on 21/10/2005) |